Human mortalin (HSPA9) was originally identified by its close homology to murine mortalins, which play important roles in cellular senescence. The two murine genes, mot-1 and mot-2, differ in only two amino acid residues, but have opposite functions in cellular immortalization. HSPA9 was recently localized to chromosome 5, band q31, a region that is frequently deleted in myeloid leukemias and myelodysplasia (MDS), making it a candidate tumor suppressor gene, which is consistent with the biological function of its murine homologue. To evaluate mortalin in this capacity, its expression in normal and leukemic cell lines was investigated, and its genomic structure was determined in order to facilitate mutation detection. RT-PCR and Northern blot analysis revealed a broad distribution in normal tissues and in leukemia cell lines, producing a single 2.8 kb transcript. Genomic characterization showed that the gene spans 18 kb, and consisted of 17 exons with boundaries that were almost identical to its murine counterpart. Using intronbased primers to flank each exon, sequence of the complete protein-coding regions was obtained for three AML cell lines, including two lines with chromosome 5 loss (KG-1 and HL-60) and one without (AML-193) compared to normal DNA. No mutations were identified although one conservative nucleotide sequence variant was observed in exon 16. We have shown that mortalin is highly conserved in genomic structure as well as sequence, and the designed primers will be suitable for future studies to detect mutations in clinical samples. Leukemia (2000) 14, 2128-2134.
Introduction
Human mortalin (also called peptide-binding protein 74 (PBP74), and heat shock 70kD protein 9 (HSPA9)) is an interesting gene that shows a high degree of nucleotide sequence homology to its murine counterparts mortalin-1 (mot-1) and mortalin-2 (mot-2). The mouse homologues were initially identified by their roles in cellular senescence, where they appear to have contrasting functions. In non-immortalized murine fibroblasts, mortalin displays a uniform pancytosolic distribution, whereas it manifests a perinuclear location in immortalized fibroblasts.
1,2 Cytosolic mot-1 has been proposed to be a major determinant of fibroblast senescence, such that its transfection into NIH3T3 cells induces cellular senescence, whereas microinjection of anti-mortalin antibody can stimulate proliferation in senescent murine fibroblasts. 3 On the other hand, over-expression of mot-2 can induce malignant transformation of NIH 3T3 cells. 4 The cytosolic and perinuclear forms of mortalin were later shown to arise from the two related genes, mot-1 and mot-2, which differ from each other by only two amino acid residues, respectively. cDNAs for both the pancytosolic form (mot-1) and the perinuclear form (mot-2) of murine mortalin have been fully cloned, and the genomic organization of mot-2 has been reported. 1, 3 Recent evidence suggests that the two mortalins are not isoforms, but instead originate from two distinct genomic loci. Fluorescence in situ hybridization assigned the mortalin-related genes to mouse chromosomes 18 and X. 6 The two forms of mortalin are variably present in different strains of mouse; thus, both mot-1 and mot-2 are present in the Balb/c strain, while Swiss and C56BL/6 mice contain only mot-2, and C3H He mice contain only mot-1. It has been suggested that this distribution of mortalin genes may explain the different rates of spontaneous immortalization of cells found in different strains of mouse. 5 Unlike murine mortalin, there appears to be only one human mortalin gene, HSPA9, which is highly homologous to both mot-1 and mot-2, differing from them in amino acid sequence by only 6 and 5 residues, respectively. HSPA9 has been assigned to chromosome 5 band q31.1. 6 Recently, we refined the location of this gene to a 700-kb interval, which we postulate to be the site of a tumor suppressor gene implicated in myeloid malignancies manifesting −5 or del(5q), including acute myeloid leukemia (AML) and myelodysplasia (MDS). 7 The chromosomal location of the mortalin gene, its biologic function in murine cells, and its association with cellular immortalization, make it an appealing candidate for a tumor suppressor gene whose mutational loss or inactivation results in transformation of myeloid cells. Here, we report the genomic structure of human mortalin, which we found to be highly similar in organization to murine mot-2. Additionally, we report intron-based primers, suitable for genomic sequencing, and their use to evaluate the mortalin coding sequence in several myeloid leukemia cell lines with −5 or del(5q).
Materials and methods

Cell culture and bacterial clones
Cell lines used in this study were obtained from ATCC (Rockville, MD, USA). Cells were cultured using recommended conditions, or in RPMI-1640 medium (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal calf serum (Sigma, St Louis, MO, USA) at 37°C in an atmosphere of 5% CO 2 in air. CD34
+ cells were isolated from bone marrow obtained from normal donors with informed consent under the guidelines provided by the University of Illinois. The CD34 + cells were isolated and purified as previously described. 8 BAC clone 15L17 was obtained from Research Genetics (Huntsville, AL, USA).
Preparation of DNA and RNA
Genomic DNA and total cellular RNA were extracted using TRIZol Reagent (Gibco Technologies, Gaithersburg, MD, USA) according to the recommended protocol from 10 7
CD34
+ cells, or from cell lines that were harvested in the logarithmic growth phase. BAC DNA was prepared according to standard protocols used in this laboratory. 9 Reverse-transcriptase PCR (RT-PCR) RT 
DNA sequencing
The DNA sequencing reaction was performed using the ABI Prism BigDye Terminator Sequencing kit (Perkin-Elmer). In brief, PCR products amplified from each exon were purified using Qiagen PCR purification kit (Qiagen, Valencia, CA, USA). A typical 20 l reaction containing 20-90 ng DNA template from purified PCR products, 0.32 M of forward or reverse primer, and 8 l of BigDye terminate mixture was reamplified as follows: 24 cycles at 96°C for 30 s, 50°C for 15 s, and 60°C for 4 min. The reactions were purified and then sequenced using an ABI prism 377 DNA sequencer (Perkin-Elmer). Analysis of the sequences was performed using Seqman software (DNASTAR, Madison, WI, USA).
Northern blot analysis
Ten micrograms of total RNA from each cell line were separated on 1.0% formaldehyde agarose gels and transferred to Hybond-N nylon filters (Amersham, Arlington Heights, IL, USA), which were subsequently cross-linked with ultraviolet light. After prehybridization at 65°C for 2 h, the blot was hybridized to ␣-32 P-dCTP-labelled cDNA probes for 18 h at 65°C, and washed with 2 × SSC + 0.1% SDS twice, followed by 1 × SSC + 0.1% SDS twice, and 0.1 × SSC + 0.1% SDS twice. The blots were exposed to X-ray films with an intensifying screen at −80°C. The same filters were subsequently Leukemia hybridized with a ␤-actin probe as an internal control of both the RNA integrity and amount. A multiple tissue Northern blot, MTN H, (Clontech, Palo Alto, CA, USA), which contained mRNAs from various human tissues including heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas was used to detect expression of mortalin. A hybridization probe was prepared from a 649-bp fragment of human mortalin containing sequences from exon 9 to exon 11 and amplified by RT-PCR from human leukemia cell line KG-1. The pair of primers used consisted of the forward primer for exon 9 (5Ј-CTGCTGAAAAGGCTAAATGTGAACTCTC-3Ј) and the reverse primer for exon 11 (5Ј-CACAGCCTCATCAG-GATTGAGAGCTT-3Ј). The RT-PCR product was labelled with ␣-32 P-dCTP by random primer labelling using Multiprime DNA Labeling System(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Results
Genomic organization of human mortalin
The intron-exon boundaries of human mortalin were predicted by alignment of the human cDNA sequence (GenBank Accession No. L15189 ) with the published intron-exon boundary sequences of murine mot-2 gene 10 using Seqman software. Exon-based primers at the presumed intron-exon boundaries were then designed to amplify intron sequences between the exons (Table 1) using DNA from BAC clone 15L17 as a template. This BAC clone was identified as containing the genomic sequence for mortalin by BAC typing in our laboratory (data not shown). In those instances in which the predicted PCR product appeared to be longer than 3.0 kb and failed to amplify, such as intron 9 (5.0 kb), long-range PCR was attempted using the Expand 20 kb Plus PCR System according to the manufacturer's instruction (Boehringer Mannheim). The PCR products obtained from this exon-toexon amplification were separated by agarose gel electrophoresis and the size of each intron was estimated by comparing with a 1 kb DNA ladder (GIBCO BRL). These amplified intron-specific sequences were then directly sequenced in both directions, and the exact positions of exon-intron boundaries were identified by comparing the genomic sequences amplified from the BAC clone with human mortalin cDNA sequence. All boundary sequences contain consensus GT/AG sequences at donor and acceptor sites; these exon-intron boundaries are given in Table 2 .
The genomic organization of the human mortalin is summarized and compared to murine mot-2 in Figure 1 ; there is no information available on the genomic organization of mot-1. The human and murine genes are remarkably similar in organization, differing primarily in intron size. In the mouse, mot-2 is 16.5 kb in length and consists of 17 exons separated by 16 introns. 5 The human mortalin gene also contains 17 exons and 16 introns and spans over 18 kb; the intron between exons 9 and 10 is the longest, being approximately 5 kb in length. All other introns are between 0.2 kb and 2.5 kb in size. The intron-exon boundaries are almost identical between the human and mouse genes and all boundary sequences contain consensus GT/AG sequences at donor and acceptor sites ( Figure 1 and Table 2 ). 
Expression
Human mortalin is known to encode an mRNA of 2.8 kb.
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As expected, Northern blot analysis confirmed that human mortalin is widely expressed in multiple tissues (Figure 2a) , with the highest expression seen in heart; expression was intermediate in skeletal muscle, kidney, liver and brain, and the lowest in lung, placenta and pancreas. Mortalin expression was also investigated in human myeloid leukemia cell lines. Using RT-PCR, the presence of mortalin transcript was confirmed in three myeloid lines and in CD34 + cells derived from human bone marrow, which are thought to contain the earliest myeloid stem cell precursors (Figure 2b 
Mutation analysis of mortalin in leukemia cell lines
The coding sequence of mortalin was investigated for mutations in three AML cell lines, including two lines with chromosome 5 deletion (KG-1 and HL-60) and one without (AML-193), by sequencing the complete coding regions of all 17 exons in genomic DNA using the intron-based primers given in Table 3 . The sequence obtained was compared to genomic sequence from BAC DNA. No mutations were detected in any of the cell lines, although a conservative nucleotide sequence variant was identified in exon 16 of the three lines comparing to BAC DNA. As shown in Figure 3 , The nucleotide numbering starts with the ATG initiation codon (A = 1). b Exon size was calculated from published cDNA sequence data and our exon-intron splicing sites. 
Discussion
Deletion of chromosome 5, del(5q), or complete loss of the entire chromosome, -5, is a recurring cytogenetic abnormality observed in myeloid malignancies. It is observed in about 20% of MDS and 10% of AML arising de novo 15, 16 and up to 40% of AML arising after previous treatment with alkylating agents and radiotherapy, namely therapy-related MDS or AML, or t-MDS/tAML. 17 Del(5q) is among the worst prognostic indicators in AML, being characterized by poor response to Leukemia chemotherapy, lower remission rate (Ͻ30%), and a short median survival. 18, 19 It has been proposed that there is a tumor suppressor gene on 5q, whose mutational inactivation contributes to myeloid malignancies. It is hypothesized that this gene, like other tumor suppressor genes which are associated with chromosomal deletions, will be functionally inactivated in AML cases with del 5q or −5. Thus, we expect in these situations, to find that one allele of this gene is deleted and the remaining allele mutated.
As an initial step in the identification of this presumed tumor suppressor gene, we and others have attempted to define a genomic region that is consistently deleted in cases of del 5q, by comparing the extent of chromosomal loss in clinical samples. 9, 20 These studies all suggest that the critical deletion interval is located at band 5q31. Recently, we further delineated this minimal interval to the D5S500-D5S594 region, an interval of about 700 kb, to which we have localized several candidate genes and ESTs including mortalin. 7 Human mortalin is an appealing candidate for a tumor suppressor gene because of both its role in cellular immortalization and its chromosomal localization within the commondeleted interval on 5q31.1 in AML/MDS. In mouse, there are two closely related forms of mortalin, of which one (mot-1) induces cellular senescence, whereas the other (mot-2) may facilitate cellular immortalization. 3, 5 Further evidence supports this viewpoint, as mot-2 co-localizes with p53 and represses p53-mediated transactivation, whereas mot-1 does not. 21 Because human mortalin closely resembles both murine mot-1 and mot-2 in amino acid sequence, it is not possible to predict which of these two isoforms most closely resembles human mortalin in function. It is tempting to speculate that the loss of human mortalin may facilitate transformation of myeloid cells, functioning like mot-1. However, the biology of the human gene has not been as extensively studied as its murine counterpart, and its cellular localization and relationship to immortalization have not been clarified. Normal human cells display a pancytosolic distribution similar to that found in normal mouse cells, whereas four kinds of distribution patterns have been described in human transformed cells, including perinuclear or juxtanuclear patterns. 2 For example, in bladder carcinoma, an overexpression of the nonpancytosolic protein was the predominant pattern, indicating that the expression of this form may play a role in malignant transformation. 4 The evidence of elevated levels of mortalin expression in human brain tumors further suggests an involvement of nonpancytosolic mortalin in tumorigenesis in vivo. 22 However, nothing is known about the expression and function of mortalin in myeloid cells, nor has the gene been examined in any human systems as a possible tumor suppressor gene.
Thus, to further evaluate mortalin as a candidate tumor suppressor gene in AML, it will be necessary to examine clinical samples for expression of the gene, and for mutations within it. Here we have begun this process by examining expression of mortalin in normal human myeloid cells and a panel of human leukemia cell lines, and by designing intron-based PCR primers which are suitable for amplification and sequencing of genomic DNA. Our data showed that mortalin is ubiquitously expressed in human tissues as well as in leukemia cell lines, although the level of expression varies considerably. A single 2.8 kb transcript of mortalin was depicted by Northern blot in all of the 13 leukemia cell lines investigated, suggesting that abnormal splicing or large deletions of the mRNA are not frequent findings in myeloid leukemias.
To prepare PCR primers for genomic sequencing of exons, it was necessary to first ascertain the gene structure and the approximate intron-exon boundaries. The intron-exon boundaries were estimated to coincide with those of murine mot-2, so genomic sequencing proceeded from these sites along a human BAC clone which contains the gene in its entirety. The human boundaries were almost identical to those of the murine gene, but the intron sequence and sizes differed, as expected. The intron sequence was then used to design PCR primers flanking each exon which were suitable for genomic sequencing, which could be used for the detection of mutations within the protein coding regions of the gene. The primers were evaluated in a small series of leukemia cell lines, including two lines with chromosome 5 deletion (KG-1 and HL-60) and one without (AML-193), as compared to BAC genomic DNA 15L17. All 17 exons of the mortalin gene were sequenced in these DNA sources, but no deviations from the normal sequence were found, except for a conservative nucleotide sequence variant in exon 16 which does not change the amino acid sequence and thus represents a single nucleotide polymorphism (SNP). Although we failed to identify mutations in these two cell lines with chromosome 5 deletions, we have demonstrated that these primers are suitable for sequence analysis of the protein-coding regions of mortalin, and will be useful for additional analysis in clinical samples. In summary, we report here the genomic organization, expression analysis, mutation analysis, and intron-based primers for human mortalin, a candidate for the myeloid leukemia tumor suppressor gene at 5q31. Application of these primers to two AML cell lines with del(5q) failed to reveal any mutations, although the sample size is small. Additional sequencing of a larger number of clinical specimens of leukemias with del(5q) is now in progress, to fully evaluate mortalin for evidence of mutational inactivation.
